;)
Morphic´s Challenge
The internal development leadership team of the Nasdaq-listed biotechnology company, Morphic Therapeutics, sought support in the clinical development planning and indication prioritization for a pre-clinical asset with a novel mechanism of action.
“The Adnovate team produced detailed and thoughtful assessments to meet our needs in our survey of the landscape of development possibilities. This collaborative effort allowed us to prioritize indications that were suitable for our execution. Adnovate’s experienced team members performed professionally and flexibly, maintaining outputs to agreed timelines, and producing high quality deliverables to help with our strategic development planning.”
Brihad Abhyankar | SVP Clinical Development
Adnovate Clinical’s Solution
Adnovate Clinical provided a cross-functional team
with relevant therapy area expertise to assess a broad range of possible indications, customizing the assessment based on the client’s specific needs.
